<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79556">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069756</url>
  </required_header>
  <id_info>
    <org_study_id>DC-PPMD-2013</org_study_id>
    <nct_id>NCT02069756</nct_id>
  </id_info>
  <brief_title>DuchenneConnect Registry</brief_title>
  <official_title>DuchenneConnect: An International, Patient-Report Registry for Individuals With Duchenne/Becker Muscular Dystrophy (Member of TREAT-NMD Neuromuscular Alliance)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DuchenneConnect</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parent Project Muscular Dystrophy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>DuchenneConnect</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DuchenneConnect is an online, patient-report registry for individuals with Duchenne and
      Becker muscular dystrophy and carrier females. The purpose of DuchenneConnect is to connect
      Duchenne and Becker patients with actively recruiting clinical trials and research studies,
      and to educate patients and families about Duchenne and Becker care and research. At the
      same time, DuchenneConnect is a valuable resource for clinicians and researchers in academia
      and industry, allowing access to a de-identified, aggregate dataset provided by patients and
      their families—information that is vital to advances in the care and treatment of Duchenne.
      DuchenneConnect is a member of PCORnet, the National Patient-Centered Clinical Research
      Network.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DuchenneConnect was created in 2007 by Parent Project Muscular Dystrophy (PPMD), with
      assistance from the NIH, the CDC, and Emory Genetics. In early 2011, PPMD alone began
      financing the registry's operation and maintenance, and is the sole guardian of
      DuchenneConnect and its material.

      Questions may be addressed to the DuchenneConnect Coordinators at telephone 888-520-8675 or
      coordinator@duchenneconnect.org. The DuchenneConnect Coordinators are certified genetic
      counselors who are available to answer questions regarding the registration process, genetic
      testing and counseling, and clinical trials and research studies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">October 2047</completion_date>
  <primary_completion_date type="Anticipated">October 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>40 Years</target_duration>
  <primary_outcome>
    <measure>Genetic mutation</measure>
    <time_frame>Registrants are requested to update their medical history every 6-12 months, and they will be followed throughout their lifetime.</time_frame>
    <description>Genetic mutation data is collected by patient report and verified by curation/review of genetic test report when provided. Genetic test report is requested for each registrant and is required for participation in global DMD (TREAT-NMD) registry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ambulation status</measure>
    <time_frame>Registrants are requested to update their medical history every 6-12 months, and they will be followed throughout their lifetime.</time_frame>
    <description>Ambulation status is assessed from several questions about mobility in home and away from home, ability to sit and stand, use of assistive devices, and age at full time wheelchair use.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Corticosteroid use</measure>
    <time_frame>Registrants are requested to update their medical history every 6-12 months, and they will be followed throughout their lifetime.</time_frame>
    <description>Data collected includes whether or not corticosteroids are used, and if so, name of corticosteroid, age started/stopped, dose and dosing regimen.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiovascular status</measure>
    <time_frame>Registrants are requested to update their medical history every 6-12 months, and they will be followed throughout their lifetime.</time_frame>
    <description>Multiple questions regarding cardiovascular symptoms, age at diagnosis of cardiomyopathy, use of cardiac medications, date of most recent echocardiogram and/or cardiac MRI, and the LVEF and/or LVSF value.</description>
  </other_outcome>
  <other_outcome>
    <measure>Respiratory status</measure>
    <time_frame>Registrants are requested to update their medical history every 6-12 months, and they will be followed throughout their lifetime.</time_frame>
    <description>Assessed from questions about use of breathing devices, age at which breathing devices were started, date of most recent pulmonary function test (spirometry), and the FVC value (% predicted and raw FVC in liters).</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <condition>Becker Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Duchenne and Becker Muscular Dystrophy</arm_group_label>
    <description>Patients with Duchenne or Becker Muscular Dystrophy, as well as carrier females.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        DuchenneConnect is primarily a United States registry, but we do welcome participants from
        other countries and we currently have over 100 countries represented in the registry.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Duchenne or Becker muscular dystrophy; Manifesting female carriers and
             asymptomatic female carriers also included in registry.

        Exclusion Criteria:

          -  Diagnosis of any other type of muscular dystrophy (including limb-girdle muscular
             dystrophy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ann Martin, MS, CGC</last_name>
    <phone>888-520-8675</phone>
    <phone_ext>option 2</phone_ext>
    <email>coordinator@duchenneconnect.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ann Lucas, MS, CGC</last_name>
    <phone>888-520-8675</phone>
    <email>coordinator@duchenneconnect.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DuchenneConnect / PPMD</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Martin, MS, CGC</last_name>
      <phone>888-520-8675</phone>
      <phone_ext>option 2</phone_ext>
      <email>coordinator@duchenneconnect.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.treat-nmd.eu/</url>
    <description>TREAT-NMD Neuromuscular Alliance</description>
  </link>
  <link>
    <url>http://www.parentprojectmd.org</url>
    <description>Parent Project Muscular Dystrophy</description>
  </link>
  <link>
    <url>http://pcornet.org/</url>
    <description>PCORnet - The National Patient-Centered Clinical Research Network</description>
  </link>
  <results_reference>
    <citation>Rangel V, Martin AS, Peay HL. DuchenneConnect Registry Report. Version 2. PLoS Curr. 2012 Feb 29 [revised 2012 Mar 13];4:RRN1309.</citation>
    <PMID>22453902</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang RT, Silverstein Fadlon CA, Ulm JW, Jankovic I, Eskin A, Lu A, Rangel Miller V, Cantor RM, Li N, Elashoff R, Martin AS, Peay HL, Halnon N, Nelson SF. Online self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits. PLoS Curr. 2014 Oct 17;6. pii: ecurrents.md.e1e8f2be7c949f9ffe81ec6fca1cce6a. doi: 10.1371/currents.md.e1e8f2be7c949f9ffe81ec6fca1cce6a.</citation>
    <PMID>25635234</PMID>
  </results_reference>
  <results_reference>
    <citation>Bladen CL, Rafferty K, Straub V, Monges S, Moresco A, Dawkins H, Roy A, Chamova T, Guergueltcheva V, Korngut L, Campbell C, Dai Y, Barišić N, Kos T, Brabec P, Rahbek J, Lahdetie J, Tuffery-Giraud S, Claustres M, Leturcq F, Ben Yaou R, Walter MC, Schreiber O, Karcagi V, Herczegfalvi A, Viswanathan V, Bayat F, de la Caridad Guerrero Sarmiento I, Ambrosini A, Ceradini F, Kimura E, van den Bergen JC, Rodrigues M, Roxburgh R, Lusakowska A, Oliveira J, Santos R, Neagu E, Butoianu N, Artemieva S, Rasic VM, Posada M, Palau F, Lindvall B, Bloetzer C, Karaduman A, Topaloğlu H, Inal S, Oflazer P, Stringer A, Shatillo AV, Martin AS, Peay H, Flanigan KM, Salgado D, von Rekowski B, Lynn S, Heslop E, Gainotti S, Taruscio D, Kirschner J, Verschuuren J, Bushby K, Béroud C, Lochmüller H. The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum Mutat. 2013 Nov;34(11):1449-57. doi: 10.1002/humu.22390.</citation>
    <PMID>23913485</PMID>
  </results_reference>
  <results_reference>
    <citation>Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L, Roy AJ, Chamova T, Guergueltcheva V, Chan S, Korngut L, Campbell C, Dai Y, Wang J, Barišić N, Brabec P, Lahdetie J, Walter MC, Schreiber-Katz O, Karcagi V, Garami M, Viswanathan V, Bayat F, Buccella F, Kimura E, Koeks Z, van den Bergen JC, Rodrigues M, Roxburgh R, Lusakowska A, Kostera-Pruszczyk A, Zimowski J, Santos R, Neagu E, Artemieva S, Rasic VM, Vojinovic D, Posada M, Bloetzer C, Jeannet PY, Joncourt F, Díaz-Manera J, Gallardo E, Karaduman AA, Topaloğlu H, El Sherif R, Stringer A, Shatillo AV, Martin AS, Peay HL, Bellgard MI, Kirschner J, Flanigan KM, Straub V, Bushby K, Verschuuren J, Aartsma-Rus A, Béroud C, Lochmüller H. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015 Apr;36(4):395-402. doi: 10.1002/humu.22758. Epub 2015 Mar 17.</citation>
    <PMID>25604253</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 21, 2016</lastchanged_date>
  <firstreceived_date>September 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne</keyword>
  <keyword>Becker</keyword>
  <keyword>Muscular Dystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
